medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2021, Number 3

<< Back

Alerg Asma Inmunol Pediatr 2021; 30 (3)

Report of two clinical cases of adolescents with severe uncontrolled refractory eosinophilic asthma treated with mepolizumab at one-year follow-up

Cerda-Reyes S, Maldonado-Hernández JG, Campos-Gutiérrez RI, Castillón-Benavides NK, Partida-Gaytán A

Language: Spanish
References: 29
Page: 104-109
PDF size: 176.69 Kb.


ABSTRACT

Introduction: Although severe asthma affects less than 5% of asthmatic patients, it always represents a diagnostic and therapeutic challenge. More than two-thirds of patients with severe asthma have evidence of eosinophilic inflammation as the main mechanism behind this clinical severity. Recently, a new humanized anti-IL5 monoclonal antibody has been approved in Mexico for the treatment of patients with severe, uncontrolled refractory eosinophilic asthma from 12 years of age. Clinical case: We share our initial clinical experience with mepolizumab through two clinical cases of adolescents with a diagnosis of severe refractory eosinophilic asthma who have received treatment with mepolizumab 100 mg subcutaneously every 30 days complementary to standard inhaled treatment. We include the clinical description that led to the decision to start mepolizumab and descriptive comparisons of different clinical variables (number of exacerbations, asthma control test score, frequency of use of rescue medications, dose of maintenance medications, changes in parameters of lung function, frequency of reported adverse events), and specific biomarkers of severe asthma (eosinophils, exhaled fraction of nitric oxide) before and after starting mepolizumab at 1 year of follow-up. Conclusion: our initial clinical experience with mepolizumab in the treatment of two adolescents with severe uncontrolled refractory eosinophilic asthma has been favorable with significant reductions in asthma exacerbations, improvement in asthma control, decrease in the frequency of use of rescue medications and improvement in lung function in both patients. This initial experience is a panorama that needs to be expanded to more patients and for a longer time to provide evidence of consistency of results observed in other populations in the context of Mexican patients with severe asthma.


REFERENCES

  1. Global Strategy for Asthma Management and Prevention [Internet]. EUA: Global Initiative for Asthma; 2021. Available in: https://ginasthma.org/gina-reports/

  2. Menezes AM, Hallal P, Montes-de Oca M, Muino A, López-Varela, Talamo C et al. Prevalence of asthma in Latin American middle-aged and older adults and its overlap with diagnosis of COPD. Eur Respir J. 2011; 38 (Suppl 55): 4136.

  3. Scichilone N, Barnes PJ, Battaglia S, Benfante A, Brown R, Canonica GW et al. The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians. J Clin Med. 2020; 9 (8): 2397. Doi: 10.3390/jcm9082397.

  4. Backman H, Jansson SA, Stridsman C, Eriksson B, Hedman L, Eklund BM et al. Severe asthma-a population study perspective. Clin Exp Allergy. 2019; 49: 819-828.

  5. Guía Española para el manejo de Asma. GEMA 5.0.

  6. McDonald VM, Kennington E, Hyland ME. Understanding the experience of people living with severe asthma. En: Chung KF, Israel E, Gibson PG, editores. Severe asthma. Reino Unido: European Respiratory Society; 2019.

  7. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med. 2006; 100 (3): 434-450. doi: 10.1016/j.rmed.2005.06.012.

  8. Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019; 68 (2): 158-166. doi: 10.1016/j.alit.2019.01.004.

  9. Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178 (3): 218-224. doi: 10.1164/rccm.200711-1754OC.

  10. De Carvalho-Pinto RM, Cukier A, Angelini L, Antonangelo L, Maud T, Rabe KF et al. Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med. 2012; 106 (1): 47-56. doi: 10.1016/j. rmed.2011.08.013.

  11. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res. 2001; 2 (2): 71-79. doi: 10.1186/rr41.

  12. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020; 55 (1): 1900588. doi: 10.1183/13993003.00588-2019.

  13. Partida-Gaytán A, Torre-Bouscoulet L, Macías MP, Raimondi A, Pizzichini E. Mepolizumab for the treatment of severe eosinophilic asthma. Revista Alergia México. 2020; 67: doi: doi.org/10.29262/ram.v67i7.780.

  14. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON et al. Mepolizumab for severe eosinophilicasthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380 (9842): 651-659. doi: 10.1016/S0140-6736(12)60988-X.

  15. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitxGerald JM, Chetta A et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371 (13): 1198-1207. doi: 10.1056/NEJMoa1403290.

  16. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371 (13): 1189-1197. doi: 10.1056/NEJMoa1403291.

  17. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM et al. Efcacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5 (5): 390-400. doi: 10.1016/S2213-2600(17)30125-X.

  18. Votto M, De Filippo M, Licari A, Marseglia A, De Amici M, Marseglia GL. Biological therapies in children and adolescents with severe uncontrolled asthma: a practical review. Biologics. 2021; 15: 133-142. doi: 10.2147/BTT.S252574.

  19. Lin CH, Cheng SL. A review of omalizumab for the management of severe asthma. Drug Des Devel Ther. 2016; 10: 2369-2378.

  20. Yancey SW, Ortega HG, Keene ON, Bradford ES. Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy Asthma Clin Immunol. 2019; 15: 53. doi: 10.1186/s13223-019-0366-x.

  21. Jocelyne Just MD, PhD, New perspectives of childhood asthma treatment with biologics,Pediatr Allergy Immunol. 2019; 30: 159-171. doi: 10.1111/pai.13007.

  22. Albers F C, Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. Journal for Asthma. (Internet) 2018; 55 (2) 152-160. Available in: https://doi.org/10.1080/02770903.2017.1322611.

  23. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014; 43: 343-373.

  24. Álvarez-Gutiérrez FJ, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero JL, Padilla A et al. Documento de consenso de asma grave en adultos. Actualización 2020. Open Respir Arch. 2020; 2 (3): 158-174.

  25. Chapman KR, Albers FC, Chipps B, Muñoz X, Devouassoux G, Bergna M et al. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy. 2019; 74 (9): 1716-1726. doi: 10.1111/all.13850.

  26. Carpagnano GE, Pelaia C, D'Amato M, Crimi N, Scichilone N,Scioscia G, Resta O, Calabrese C, Pelaia G, Quarato CMI, Foschino Barbaro MP. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020; 14:1753466620929231. doi: 10.1177/17534666209231.

  27. Hoshi M, Matsunaga M, Nogami K, Hamada K, Kobori T, Kainuma K, Nagao M, Fujisawa T. Three cases of severe adolescent asthma treated with mepolizumab: lung function trajectories. Asia Pac Allergy. 2020; 10 (2): e13. doi: 10.5415/apellergy.2020. 10.e13.

  28. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG et al. Long-term ef cacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016; 38 (9): 2058-2070.e1. doi: 10.1016/j.clinthera.2016.07.010.

  29. Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S et al. Long-term safety and clinical bene t of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019; 41 (10): 2041-2056. e5. doi: 10.1016/j.clinthera.2019.07.007.




2020     |     www.medigraphic.com